BOCCO JOSE LUIS
Congresos y reuniones científicas
Título:
Alkaloids with Synthetic Lethal Activity AgainsT BRCA-Deficient Cells Isolated from Zanthoxylum coco.
Autor/es:
PANSA M. F.; PACCIARONI A.; ANGIOLINI V.; CARABAJOSA S.; BARBOZA G. E.; BOCCO J.L.; NICOTRA V. E.; SORIA G.
Lugar:
Paraná - Entre Ríos
Reunión:
Congreso; LIV Reunión Anual de la Sociedad Argentina de Investigación en Bioquímica y Biología Molecular; 2018
Institución organizadora:
Sociedad Argentina de Investigación en Bioquímica y Biología Molecular
Resumen:
The design of drug discovery strategies for cancer research is one of the most challenging efforts to develop novel targeted therapies. Synthetic lethality (SL) is a state-of-the-art precision strategy for cancer treatment that is based on the induction of selective toxicity against cancerous cells with certain genetic defects. Since mutations or epigenetic down-regulation of BRCA genes are known drivers of hereditary types of breast and ovarian cancers, they can be used as tools in phenotypic screenings to identify novel synthetic lethality inducers.Due to their broad chemical diversity, natural products are an important source of lead molecules for drug discovery. In this work we evaluated pure compounds and extracts from ≈200 plant species from Argentina using an innovative screening platform based on automated flow cytometry. We found that the alkaline extract from Zanthoxilum coco induce SL in BRCA-deficient cells. To identify the active metabolite/s, we performed bio-guided isolation following a sub-fractionation process and semi-preparative HPLC. Using spectroscopic methods (NMR) we were able to identify a set of benzophenantridine alkaloids as the responsible compounds of this activity. Early validation experiments using BRCA-KO cell lines and commercially available alkaloids from the same family confirmed our findings. In conclusion, this work put forward the Benzophenantridine alkaloids from Zanthoxylum coco as promising molecules for target identification and drug development to treat BRCA-deficient cancers.